EI
IOVA icon

EAM Investors’s Iovance Biotherapeutics IOVA Stock Holding History

EAM Investors’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-213,336
Closed -$3.16M – 298
2024
Q1 		$3.16M Buy
+213,336
New +$2.48M 0.49% 113
2020
Q3 		– Sell
-53,143
Closed -$1.46M – 316
2020
Q2 		$1.46M Sell
53,143
-18,629
-26% -$612K 0.32% 151
2020
Q1 		$2.15M Buy
71,772
+15,946
+29% +$423K 0.67% 46
2019
Q4 		$1.54M Buy
55,826
+2,564
+5% +$58.3K 0.34% 138
2019
Q3 		$969K Sell
53,262
-23,477
-31% -$519K 0.26% 173
2019
Q2 		$1.88M Buy
+76,739
New +$1.16M 0.46% 75
2018
Q2 		– Sell
-223,029
Closed -$3.77M – 317
2018
Q1 		$3.77M Buy
+223,029
New +$3.38M 0.63% 33

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

EAM Investors's IOVA Position: Q2 2024 in Review

EAM Investors sold out of Iovance Biotherapeutics (IOVA) in Q2 2024, closing a stake of 213,336 shares — an estimated $3.16M sold.

EAM Investors first reported a position in IOVA in Q1 2018 and held it in 7 quarters. The position peaked at $3.77M in Q1 2018. 295 funds tracked by Wall St. Rank hold IOVA as of Q2 2024.

  • EAM Investors reported no remaining Iovance Biotherapeutics position as of Q2 2024 after selling out during the quarter.
  • EAM Investors sold 213,336 Iovance Biotherapeutics shares in Q2 2024, an estimated $3.16M.
  • EAM Investors first reported a position in Iovance Biotherapeutics in Q1 2018 and held it in 7 quarters.
  • EAM Investors's Iovance Biotherapeutics position peaked at $3.77M in Q1 2018.
  • 295 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2024.

Based on EAM Investors's 13F filing for Q2 2024, filed 12 Aug 2024.